284 related articles for article (PubMed ID: 24839182)
1. Prognostic significance of spontaneous antibody responses against tumor-associated antigens in malignant melanoma patients.
Zörnig I; Halama N; Lorenzo Bermejo J; Ziegelmeier C; Dickes E; Migdoll A; Kaiser I; Waterboer T; Pawlita M; Grabe N; Ugurel S; Schadendorf D; Falk C; Eichmüller SB; Jäger D
Int J Cancer; 2015 Jan; 136(1):138-51. PubMed ID: 24839182
[TBL] [Abstract][Full Text] [Related]
2. Defining the role of CD2 in disease progression and overall survival among patients with completely resected stage-II to -III cutaneous melanoma.
Harcharik S; Bernardo S; Moskalenko M; Pan M; Sivendran M; Bell H; Hall LD; Castillo-Martín M; Fox K; Cordon-Cardo C; Chang R; Sivendran S; Phelps RG; Saenger Y
J Am Acad Dermatol; 2014 Jun; 70(6):1036-44. PubMed ID: 24698703
[TBL] [Abstract][Full Text] [Related]
3. Metastatic melanoma: spontaneous occurrence of auto antibodies is a good prognosis factor in a prospective cohort.
Maire C; Vercambre-Darras S; Devos P; D'Herbomez M; Dubucquoi S; Mortier L
J Eur Acad Dermatol Venereol; 2013 Jan; 27(1):92-6. PubMed ID: 22145691
[TBL] [Abstract][Full Text] [Related]
4. High GDF-15 Serum Levels Independently Correlate with Poorer Overall Survival of Patients with Tumor-Free Stage III and Unresectable Stage IV Melanoma.
Weide B; Schäfer T; Martens A; Kuzkina A; Uder L; Noor S; Garbe C; Harter PN; Mittelbronn M; Wischhusen J
J Invest Dermatol; 2016 Dec; 136(12):2444-2452. PubMed ID: 27705749
[TBL] [Abstract][Full Text] [Related]
5. Pretreatment levels of peripheral neutrophils and leukocytes as independent predictors of overall survival in patients with American Joint Committee on Cancer Stage IV Melanoma: results of the EORTC 18951 Biochemotherapy Trial.
Schmidt H; Suciu S; Punt CJ; Gore M; Kruit W; Patel P; Lienard D; von der Maase H; Eggermont AM; Keilholz U; ;
J Clin Oncol; 2007 Apr; 25(12):1562-9. PubMed ID: 17443000
[TBL] [Abstract][Full Text] [Related]
6. Endogenous immune response to early- and intermediate-stage melanoma is correlated with outcomes and is independent of locoregional relapse and standard prognostic factors.
Litvak DA; Gupta RK; Yee R; Wanek LA; Ye W; Morton DL
J Am Coll Surg; 2004 Jan; 198(1):27-35. PubMed ID: 14698308
[TBL] [Abstract][Full Text] [Related]
7. Tissue microarray evaluation of Melanoma antigen E (MAGE) tumor-associated antigen expression: potential indications for specific immunotherapy and prognostic relevance in squamous cell lung carcinoma.
Bolli M; Kocher T; Adamina M; Guller U; Dalquen P; Haas P; Mirlacher M; Gambazzi F; Harder F; Heberer M; Sauter G; Spagnoli GC
Ann Surg; 2002 Dec; 236(6):785-93; discussion 793. PubMed ID: 12454517
[TBL] [Abstract][Full Text] [Related]
8. Prognostic Value of 25-hydroxyvitamin D3 Levels at Diagnosis and During Follow-up in Melanoma Patients.
Saiag P; Aegerter P; Vitoux D; Lebbé C; Wolkenstein P; Dupin N; Descamps V; Aractingi S; Funck-Brentano E; Autier P; Dragomir M; Boniol M
J Natl Cancer Inst; 2015 Dec; 107(12):djv264. PubMed ID: 26376687
[TBL] [Abstract][Full Text] [Related]
9. Human high molecular weight-melanoma associated antigen mimicry by mouse anti-idiotypic monoclonal antibody MK2-23: modulation of the immunogenicity in patients with malignant melanoma.
Mittelman A; Chen GZ; Wong GY; Liu C; Hirai S; Ferrone S
Clin Cancer Res; 1995 Jul; 1(7):705-13. PubMed ID: 9816036
[TBL] [Abstract][Full Text] [Related]
10. Highly sensitive multivariable assay detection of melanocytic differentiation antigens and angiogenesis biomarkers in sentinel lymph nodes with melanoma micrometastases.
Vitoux D; Mourah S; Kerob D; Verola O; Basset-Seguin N; Baccard M; Schartz N; Ollivaud L; Archimbaud A; Servant JM; Revol M; Toubert ME; Podgorniak MP; Plassa F; Porcher R; Lebbé C
Arch Dermatol; 2009 Oct; 145(10):1105-13. PubMed ID: 19841396
[TBL] [Abstract][Full Text] [Related]
11. Molecular and biochemical testing in stage III melanoma: multimarker reverse transcriptase-polymerase chain reaction assay of lymph fluid after lymph node dissection and preoperative serum lactate dehydrogenase level.
Nowecki ZI; Rutkowski P; Kulik J; Siedlecki JA; Ruka W
Br J Dermatol; 2008 Sep; 159(3):597-605. PubMed ID: 18616789
[TBL] [Abstract][Full Text] [Related]
12. Sarcopenia as a prognostic factor among patients with stage III melanoma.
Sabel MS; Lee J; Cai S; Englesbe MJ; Holcombe S; Wang S
Ann Surg Oncol; 2011 Dec; 18(13):3579-85. PubMed ID: 21822551
[TBL] [Abstract][Full Text] [Related]
13. D-dimers in malignant melanoma: Association with prognosis and dynamic variation in disease progress.
Desch A; Gebhardt C; Utikal J; Schneider SW
Int J Cancer; 2017 Feb; 140(4):914-921. PubMed ID: 27813063
[TBL] [Abstract][Full Text] [Related]
14. Predictive factors for the development of brain metastasis in advanced unresectable metastatic melanoma.
Bedikian AY; Wei C; Detry M; Kim KB; Papadopoulos NE; Hwu WJ; Homsi J; Davies M; McIntyre S; Hwu P
Am J Clin Oncol; 2011 Dec; 34(6):603-10. PubMed ID: 21150567
[TBL] [Abstract][Full Text] [Related]
15. Sex is an independent prognostic indicator for survival and relapse/progression-free survival in metastasized stage III to IV melanoma: a pooled analysis of five European organisation for research and treatment of cancer randomized controlled trials.
Joosse A; Collette S; Suciu S; Nijsten T; Patel PM; Keilholz U; Eggermont AM; Coebergh JW; de Vries E
J Clin Oncol; 2013 Jun; 31(18):2337-46. PubMed ID: 23690423
[TBL] [Abstract][Full Text] [Related]
16. Prognostic value of serial blood S100B determinations in stage IIB-III melanoma patients: a corollary study to EORTC trial 18952.
Bouwhuis MG; Suciu S; Kruit W; Salès F; Stoitchkov K; Patel P; Cocquyt V; Thomas J; Liénard D; Eggermont AM; Ghanem G;
Eur J Cancer; 2011 Feb; 47(3):361-8. PubMed ID: 21087856
[TBL] [Abstract][Full Text] [Related]
17. Prognostic factors in metastatic melanoma patients treated with biochemotherapy and maintenance immunotherapy.
Minor DR; Moore D; Kim C; Kashani-Sabet M; Venna SS; Wang W; Boasberg P; O'Day S
Oncologist; 2009 Oct; 14(10):995-1002. PubMed ID: 19776094
[TBL] [Abstract][Full Text] [Related]
18. Correlation of positive RT-PCR for tyrosinase in peripheral blood of malignant melanoma patients with clinical stage, survival and other risk factors.
Proebstle TM; Jiang W; Högel J; Keilholz U; Weber L; Voit C
Br J Cancer; 2000 Jan; 82(1):118-23. PubMed ID: 10638977
[TBL] [Abstract][Full Text] [Related]
19. Is sex an independent prognostic factor in cutaneous head and neck melanoma?
Arce PM; Camilon PR; Stokes WA; Nguyen SA; Lentsch EJ
Laryngoscope; 2014 Jun; 124(6):1363-7. PubMed ID: 24122966
[TBL] [Abstract][Full Text] [Related]
20. Immune response to polyvalent melanoma cell vaccine in AJCC stage III melanoma: an immunologic survival model.
Jones RC; Kelley M; Gupta RK; Nizze JA; Yee R; Leopoldo Z; Qi K; Stern S; Morton DL
Ann Surg Oncol; 1996 Sep; 3(5):437-45. PubMed ID: 8876885
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
